Human Coronavirus NL63: A Common Respiratory Illness

Human coronavirus NL63, usually written HCoV-NL63, is one of the four seasonal coronaviruses that circulate worldwide and account for a sizable share of common colds and upper respiratory infections. First isolated in the Netherlands in 2004 from a seven-month-old infant with respiratory symptoms, NL63 has since been linked to roughly one in ten respiratory illnesses in some populations and carries a surprisingly strong connection to childhood croup.¹ It also shares the same cell-entry receptor as SARS-CoV-2, the virus behind COVID-19, which raises questions about why the two cause such dramatically different diseases.

What an NL63 Infection Looks and Feels Like

For most people, NL63 infection is indistinguishable from any other common cold. Cough, mild fever, and a runny nose are the hallmarks. In young children, the virus has a well-documented tendency to move into the lower respiratory tract, producing bronchiolitis and wheezing, but it still resolves on its own in the vast majority of cases.² Australian hospital data found that among patients who tested positive for NL63, about four in five were diagnosed with lower respiratory tract disease, with abnormal chest X-rays in over half and wheezing in nearly half.³ That sounds alarming, but those figures come from hospitalized patients; the overwhelming majority of NL63 infections never reach a hospital at all.

Like influenza, NL63 follows a winter pattern. A three-year surveillance study using multiplex testing for seasonal coronaviruses found that NL63, along with its relatives 229E, OC43, and HKU1, was detected almost exclusively between December and April and essentially disappeared in the summer months.⁴ If you or your child picks up a stubborn cold in January or February that never quite develops into something worse, NL63 is one of the likely suspects.

The Strongest Link Between NL63 and Croup

Croup, the barking-seal cough that frightens parents of toddlers, is probably the single most distinctive clinical feature of NL63 infection. Parainfluenza viruses have traditionally been considered the primary cause of croup, and they still account for many cases. But multiple studies from different countries have shown that NL63 is a surprisingly frequent trigger.

A large study of lower respiratory tract infection samples found that children with high NL63 viral loads and no co-infecting virus were about six and a half times more likely to have croup than children who tested negative for NL63.⁵ A Taiwanese study put the odds even higher, finding that NL63 was the most common single pathogen in croup patients, responsible for about 15 percent of croup cases overall, with an odds ratio for croup in NL63-infected children of over 43 compared to uninfected children.⁶ Among hospitalized croup patients in another study, NL63 was the second most common virus found, present in about 17 percent of cases, trailing only parainfluenza type 1. NL63-positive croup patients tended to be younger, with a median age of about 13 months, compared to 21 months for parainfluenza.⁷

The overlap between NL63’s winter peak and the peak croup season strengthens the association. If your toddler develops that characteristic barking cough and stridor during winter months, NL63 is one of the viruses most likely to be involved, though treatment for croup itself (cool mist, corticosteroids, and sometimes nebulized epinephrine) is the same regardless of which virus triggers it.

When NL63 Becomes Dangerous

In healthy adults, NL63 infection is mild enough that most people never know which virus is making them sniffle. The concern shifts when the virus reaches populations with weakened defenses. Elderly residents of care facilities, young infants, and people with compromised immune systems face the highest risk of serious outcomes.

A 2017 outbreak in a long-term care facility in Louisiana illustrates the potential. Of twenty case-patients in the facility, six were hospitalized with pneumonia, and three died.⁸ That kind of fatality rate would be unremarkable for influenza in the same setting, but it’s a reminder that “common cold coronavirus” does not mean harmless in every context.

Children are not immune to severe disease either. In 2018, a cluster of NL63 cases in Guangzhou, China, led to 23 hospitalized children, most of whom had severe pneumonia or acute bronchitis.⁹ That cluster was associated with a particular subgenotype of NL63, raising the possibility that not all NL63 strains carry the same risk. Still, outbreaks this severe remain uncommon enough that they get published as noteworthy events.

The ACE2 Receptor Puzzle

One of the more puzzling aspects of NL63 is that it uses the same doorway into human cells as SARS-CoV and SARS-CoV-2: a protein on cell surfaces called ACE2 (angiotensin-converting enzyme 2).¹⁰ At first glance, this seems like it should make NL63 similarly dangerous. But it doesn’t, and the structural explanation is genuinely interesting.

When researchers solved the crystal structure of NL63’s spike protein bound to ACE2, they found that NL63 and SARS-CoV have completely different structural architectures in the parts of their spike proteins that grab onto the receptor. There is no structural similarity in their receptor-binding domains or their receptor-binding motifs. Yet both viruses happen to latch onto the same region of ACE2, largely because that spot on ACE2 acts as a kind of “binding hotspot” that viruses from unrelated lineages have independently stumbled upon through evolution.¹¹

NL63 binds ACE2 with lower efficiency than SARS-CoV-2, and it primarily targets ciliated respiratory cells in the upper and middle airways rather than deep lung tissue. Laboratory work on human airway tissue cultures showed that NL63 replication was closely tied to how much ACE2 the cells expressed, and that three-dimensional airway tissue models (which better mimic real airways) expressed more ACE2 and were more susceptible to NL63 than flat single-layer cell cultures.¹² In short, NL63 uses the same lock, but it’s a weaker key, and it tends to stay higher in the airways where the consequences are less severe.¹³

Nearly Everyone Has Been Exposed

By the time you reach adulthood, you have almost certainly been infected with NL63 at least once, probably more than once. Seroprevalence data, which tracks how many people carry antibodies to a particular virus, makes this clear. In a study of children in Guangzhou, China, antibodies to NL63 were present in about 80 percent of infants under six months, reflecting maternal antibodies passed through the placenta. Those antibodies waned sharply between six and twelve months (falling to about 46 percent), then climbed steadily as children caught the virus themselves. By the preschool years, over 64 percent were seropositive, and by ages 16 to 18, over 96 percent carried NL63 antibodies.¹⁴

A separate study of children in the Philippines found NL63 seroprevalence of about 71 percent by ELISA testing, with seropositivity to all four seasonal coronaviruses reaching roughly 80 percent by ages two to three.¹⁵ These numbers are consistent across geographies: NL63 circulates everywhere and infects nearly everyone early in life. The reason you keep catching it is that immunity is incomplete and relatively short-lived, much like the common cold coronaviruses more broadly.

Where NL63 Came From

Like SARS-CoV and SARS-CoV-2, NL63 appears to have originated in bats. Molecular clock analysis traced the ancestry of NL63 back to a bat alphacoronavirus found in the North American tricolored bat, estimating that the two lineages shared a common ancestor roughly 560 to 820 years ago. Researchers even showed that NL63 could replicate in immortalized lung cells from that bat species, supporting the idea that coronaviruses can circulate between bats and humans over long time periods.¹⁶

Since making the jump to humans, NL63 has continued to evolve. Genomic analysis of NL63 samples has revealed a mosaic genome structure with evidence of recombination, meaning different strains exchange chunks of genetic material when they co-infect the same person.¹⁷ Surveillance in Colorado between 2005 and 2010 identified three distinct genotypes (labeled A, B, and C) circulating simultaneously, with clear signs of recombination between strains.¹⁸ This ongoing genetic shuffling is part of how NL63 evades the immune system well enough to reinfect people throughout their lives.

How NL63 Dodges the Immune System

Beyond genetic diversity, NL63 carries molecular tools that actively interfere with the body’s antiviral alarm system. One key mechanism involves a viral protein called a papain-like protease (PLP2). This protein moonlights: it processes the virus’s own proteins so they can function, and it also strips ubiquitin and a related molecule (ISG15) off host-cell proteins, which are signals the cell uses to mount an immune response. Perhaps more importantly, PLP2 directly blocks the production of type I interferon, one of the first chemical alarms the body sends out when it detects a viral invader.¹⁹

Researchers found that these two activities, stripping off ubiquitin and blocking interferon, operate through different mechanisms. Blocking the enzyme’s ability to chop proteins didn’t prevent it from suppressing interferon. This means the virus has at least two independent ways of dampening your immune response through a single protein, which makes it a harder target for any drug aimed at just one of those functions.

Cross-Reactivity With COVID-19 Vaccines

Since NL63 and SARS-CoV-2 both use ACE2, researchers have asked whether immunity to one might offer any protection against the other, and vice versa. The answer, so far, is a qualified “a little, but not much.”

Studies of COVID-19 mRNA vaccines (specifically Moderna’s mRNA-1273) found that vaccination could generate antibodies that cross-reacted with NL63. When tested in a live-virus neutralization assay, these cross-reactive antibodies showed detectable but weak neutralizing activity against NL63.²⁰ Crucially, the vaccine did not boost antibody levels that people already had against NL63 from prior natural infection. So getting a COVID-19 shot doesn’t strengthen your existing NL63 immunity, and whatever cross-reactive antibodies it produces are too feeble to meaningfully protect against NL63. The relationship appears to be an evolutionary coincidence rather than a useful medical bridge.

Beyond the Lungs

While NL63 is overwhelmingly a respiratory virus, there is growing recognition that it can occasionally affect the central nervous system. All seven known human coronaviruses have some documented associations with neurological symptoms. For NL63, this most commonly manifests as febrile seizures in infants and young children, which are triggered by high fever rather than direct viral invasion of the brain. In rare cases, more serious neurological involvement has been reported, including encephalitis in otherwise healthy older children. NL63’s neurotropism, its ability to reach and affect nerve tissue, is thought to depend on how much ACE2 receptor is expressed on cells in the nervous system.²¹

These neurological complications are rare enough that they make the medical literature as individual case reports. For the average parent dealing with a feverish toddler who has NL63, the risk of anything beyond a respiratory illness is very low. But the possibility is worth knowing about, particularly in a child who develops unusually high fevers or any change in mental status during what seems like a routine cold.

Treatment and the Search for Antivirals

There is no vaccine against NL63 and no approved antiviral specifically targeting it. Treatment is supportive: manage the fever, keep fluids up, and treat specific complications like croup with corticosteroids when needed. For the vast majority of infections, this is all that’s necessary.

Laboratory work has identified a handful of compounds that can block NL63 replication in cell cultures. One early screen tested 28 compounds and found six that inhibited the virus at early stages of its replication cycle, including small interfering RNAs (which silence specific viral genes), intravenous immunoglobulins, and the nucleoside analogue beta-D-N4-hydroxycytidine.²² That last compound is noteworthy because a derivative of it, molnupiravir, eventually became an approved antiviral for COVID-19. Whether any of these lab findings will translate into NL63-specific therapies remains an open question. Given that the virus causes mild illness in most people, the economic incentive to develop a dedicated NL63 drug is slim.

Diagnosis, for its part, has become routine in hospitals that use respiratory pathogen panels. Multiplex PCR assays can detect NL63 alongside the other three seasonal coronaviruses, influenza, respiratory syncytial virus, and other common culprits in a single nasal swab. One validated assay achieved detection sensitivity as low as 30 copies per reaction for NL63.²³ In practice, however, most people with a cold never get tested for specific viruses, and knowing it’s NL63 rather than another cold virus rarely changes what you’d do about it.

An Unusual Genome

NL63 belongs to the alphacoronavirus genus, making it a distant cousin of the betacoronaviruses that include SARS-CoV-2, MERS-CoV, and the seasonal viruses OC43 and HKU1. Its genome is roughly 27,500 nucleotides long, organized in the standard coronavirus gene order, but it stands out for having an unusually low GC content of about 34 percent, which is notably lower than other coronaviruses.²⁴ The biological significance of this skewed nucleotide composition is still debated, but it may reflect long adaptation to the human host or constraints on how the virus interacts with human cellular machinery. Two regions of the genome show the most variation between strains: one within a gene involved in replication and one in the spike gene, which is the protein the virus uses to grab ACE2.¹⁷ Variation in the spike gene is particularly relevant because it’s the part of the virus the immune system targets most. The more the spike changes, the easier it is for NL63 to slip past antibodies from a previous infection and start another round.